Cell therapies being developed to treat a range of conditions could be improved by a chemical compound that aids their survival, research suggests. Lab tests found that the human-made molecule — a type of antioxidant — helps to shield healthy cells from damage such as would be caused when they are transplanted into a patient during cell therapy.
Hormone replacement therapy (HRT) can slow the decline in lung function in middle-aged women, according to new research.
An investigational treatment that mimics a key clotting enzyme is effective, safe, and may one day eliminate the need for blood products for people with the rare, life-threatening blood disease hereditary thrombotic thrombocytopenic purpura (TTP), according to a study.
Investigators have uncovered a new genetic cause of mesothelioma: a genetic rearrangement in the ALK gene, observed in three patients with peritoneal mesothelioma. Unlike previously known causes, this new discovery points to a potential therapeutic approach for those few patients whose tumors harbor the mutation.
Thirty percent of type 2 diabetic patients don’t begin insulin when it’s initially recommended, with the average start time being two years later.
Antibody treatment reduces rate of flare-ups in patients with a subgroup of treatment-resistant COPD, new research indicates.
A protein, called inositol-requiring enzyme 1 — IRE1 — may serve as a key driver in a series of molecular interactions that can both promote and, paradoxically, inhibit tumors in certain types of cancers, such as non-melanoma skin cancers, according to a team of molecular biologists. They add that this pathway’s dual power may make it a tempting target for future research on the design of new types of anti-cancer therapeutics.
Researchers successfully used a gene that suppresses cholesterol levels as part of a treatment to reduce plaque in mice with a disorder called familial hypercholesterolemia. In a preclinical study, researchers found that the gene, LeXis, lowered cholesterol and blockages in the arteries, and the treatment appeared to reduce the build-up of fat in liver cells.
A major international study has found that the combination of two drugs — rivaroxaban and aspirin — is superior to aspirin alone in preventing further heart complications in people with vascular disease. The study of 27,400 people with stable coronary or peripheral artery disease from 33 countries worldwide shows that the combination of 2.5 mg of rivaroxaban twice daily plus 100 mg of aspirin once daily was significantly better than only aspirin or only rivaroxaban in preventing heart attacks, strokes and early death.
Researchers report encouraging preclinical results as they pursue elusive therapies that can repair scarred and poorly functioning heart tissues after cardiac injury. Scientists inhibited a protein that helps regulate the heart’s response to adrenaline, alleviating the disease processes in mouse models and human cardiac cells.